Health Condition 1: C53- Malignant neoplasm of cervix uteri Health Condition 2: C18- Malignant neoplasm of colon Health Condition 3: C15- Malignant neoplasm of esophagus Health Condition 4: C23- Malignant neoplasm of gallbladder Health Condition 5: C22- Malignant neoplasm of liver and intrahepatic bile ducts Health Condition 6: C56- Malignant neoplasm of ovary Health Condition 7: C25- Malignant neoplasm of pancreas Health Condition 8: C16- Malignant neoplasm of stomach Health Condition 9: C50-C5
Conditions
Interventions
Intervention1: Nil: Nil
Sponsors
Strand Life Science Private Limited
Eligibility
Inclusion criteria
Inclusion criteria: Cohort 1 1. Patients with pathologically confirmed malignancy of breast, cervix, colorectal, esophagus, lung, stomach, liver, gallbladder, pancreas and ovary, as identified by the site Principal Investigator or Co-Investigators. 2. Patients diagnosed with clinical staging I, II and III only 3. Patients who are treatment-naïve (no prior chemotherapy or oncosurgery or oncotherapy or any oncology investigational agent(s)) 4. Willingness to be recontacted by the PI for gathering future clinical status 5. Willingness to provide informed consent Cohort 2 1. Healthy volunteers with no known symptoms suggestive of cancer including benign, precancerous lesions as identified by the site Principal Investigator or Co-Investigators through routine clinical care processes. 2. Willingness to provide informed consent.
Exclusion criteria
Exclusion criteria: Cohorts 1 and 2 1. Subjects below 18 years 2. Subjects who have an active or chronic infection 3. Women who are pregnant or suspect they are pregnant and lactating mothers 4. Cases with prior diagnostic complications or unconventional pathology or rare/unclassified tumor subtypes 5. Subjects with prior history of malignancy (other than the current primary for Cohort 1) 6. Subjects with benign, borderline, or precancerous conditions 7. Subjects with significant comorbidities that, in the opinion of the investigator, may confound study results (e.g., autoimmune disorders, recent major surgery, organ failure, etc.)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Validation of CancerSpotTM will aid in early detection of cancer, and aid in future population screening for early detection of cancer.Timepoint: Preliminary assessment at 10 percent of recruitment Final assessment at the end of recruitment | — |
Secondary
| Measure | Time frame |
|---|---|
| NILTimepoint: NIL | — |
Countries
India
Contacts
Public ContactDr Vamsi Veeramachaneni
Strand Life Sciences Private Limited
Outcome results
None listed